Late thyroid complications in survivors of childhood acute leukemia. An L.E.A. study
Claire Oudin,
Pascal Auquier,
Yves Bertrand,
Philippe Chastagner,
Justyna Kanold,
Maryline Poirée,
Sandrine Thouvenin,
Stephane Ducassou,
Dominique Plantaz,
Marie-Dominique Tabone,
Jean-Hugues Dalle,
Virginie Gandemer,
Patrick Lutz,
Anne Sirvent,
Virginie Villes,
Vincent Barlogis,
André Baruchel,
Guy Leverger,
Julie Berbis,
Gérard Michel
Affiliations
Claire Oudin
Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, France;Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Pascal Auquier
Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Yves Bertrand
Department of Pediatric Hematology and Oncology, University Hospital of Lyon, France
Philippe Chastagner
Department of Pediatric Onco-Haematology, Children’s Hospital of Brabois, Vandoeuvre Les Nancy, France
Justyna Kanold
Department of Pediatric Hematology and Oncology, CIC Inserm 501, University Hospital of Clermont-Ferrand, France
Maryline Poirée
Pediatric Hematology and Oncology Department, University Hospital L’Archet, Nice, France
Sandrine Thouvenin
Pediatric Hematology, University Hospital, Saint Etienne, France
Stephane Ducassou
Department of Pediatric Hematology and Oncology, University Hospital of Bordeaux, France
Dominique Plantaz
Department of Pediatric Hematology-Oncology, University Hospital of Grenoble, France
Marie-Dominique Tabone
Pediatric Hematology Department, Trousseau Hospital, Paris, France
Jean-Hugues Dalle
Pediatric Hematology Department, Robert Debré Hospital, Paris, France
Virginie Gandemer
Department of Pediatric Hematology and Oncology, University Hospital of Rennes, France
Patrick Lutz
Department of Pediatric Hematology-Oncology, University Hospital, Strasbourg, France
Anne Sirvent
Pediatric Hematology and Oncology Department, University Hospital, Montpellier, France
Virginie Villes
Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Vincent Barlogis
Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, France;Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
André Baruchel
Pediatric Hematology Department, Robert Debré Hospital, Paris, France
Guy Leverger
Pediatric Hematology Department, Trousseau Hospital, Paris, France
Julie Berbis
Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Gérard Michel
Department of Pediatric Hematology and Oncology, Timone Enfants Hospital and Aix-Marseille University, France;Research Unit EA 3279 and Department of Public Health, Aix-Marseille University and Timone Hospital Marseille, France
Thyroid complications are known side effects of irradiation. However, the risk of such complications in childhood acute leukemia survivors who received either central nervous system irradiation or hematopoietic stem cell transplantation is less described. We prospectively evaluated the incidence and risk factors for thyroid dysfunction and tumors in survivors of childhood acute myeloid or lymphoid leukemia. A total of 588 patients were evaluated for thyroid function, and 502 individuals were assessed for thyroid tumors (median follow-up duration: 12.6 and 12.5 years, respectively). The cumulative incidence of hypothyroidism was 17.3% (95% CI: 14.1–21.1) and 24.6% (95% CI: 20.4–29.6) at 10 and 20 years from leukemia diagnosis, respectively. Patients who received total body irradiation (with or without prior central nervous system irradiation) were at higher risk of hypothyroidism (adjusted HR: 2.87; P=0.04 and 2.79, P=0.01, respectively) as compared with transplanted patients who never received any irradiation. Patients transplanted without total body irradiation who received central nervous system irradiation were also at higher risk (adjusted HR: 3.39; P=0.02). Patients irradiated or transplanted at older than 10 years of age had a lower risk (adjusted HR: 0.61; P=0.02). Thyroid malignancy was found in 26 patients (5.2%). Among them, two patients had never received any type of irradiation: alkylating agents could also promote thyroid cancer. The cumulative incidence of thyroid malignancy was 9.6% (95% CI: 6.0–15.0) at 20 years. Women were at higher risk than men (adjusted HR: 4.74; P=0.002). In conclusion, thyroid complications are frequent among patients who undergo transplantation after total body irradiation and those who received prior central nervous system irradiation. Close monitoring is thus warranted for these patients. Clinicaltrials.gov identifier: NCT 01756599.